PNNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PNNT is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading just below resistance with a weak technical setup, no strong proprietary buy signal, and analyst targets have been drifting lower. I would not buy it now and would wait for clearer improvement in price trend and fundamentals.
Pre-market price is 3.945, up 0.90%, but the broader setup remains bearish. MACD histogram is -0.032 and still below zero, RSI_6 at 39.612 is weak but not oversold, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is near the pivot at 3.959, with immediate resistance at 4.237 and support at 3.682. The short-term pattern data suggests only modest upside near term and a negative one-month tendency.
["Pre-market price is positive, showing some early bid support.", "Analysts at Truist still keep a Buy rating despite lowering the target.", "Valuation remains a support point in analyst commentary for the BDC group.", "Open interest is relatively balanced rather than heavily bearish."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Analyst price targets have been cut multiple times, from $6 to $5 and then to $4 from one broker.", "Q2 results were weak, with a loss of 4c/share and net losses of $11.7M driven by unrealized losses.", "Insiders are selling, and selling activity rose 378.26% over the last month.", "Hedge funds are neutral with no strong accumulation trend.", "No recent congress trading data is available.", "Technical trend is bearish with MACD below zero and bearish moving averages."]
Latest quarter season: Q2. The most recent financial snapshot was unavailable, but the available earnings commentary indicates weakness in Q2: PennantPark lost 4c/share and posted net losses of $11.7M, or 18c/share, mainly from unrealized losses on its PSLF JV and spread widening. That points to a soft growth trend and pressure on profitability.
The analyst trend has turned more cautious. Truist lowered its target to $5 from $6 while keeping Buy, Oppenheimer cut its target to $5 from $6 and stayed Perform, and Keefe Bruyette reduced targets twice to $4.50 and then $4 while maintaining Underperform. Wall Street is split, but the recent direction is clearly downward on price targets, with the bearish camp gaining traction. Pros: valuation support and still one Buy rating. Cons: repeated target cuts, weak quarterly performance, and worsening credit quality commentary.
